Paper Details

  1. Home
  2. Paper Details

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

Author: BrandesDavid W, MosesHarold

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This paper reviews the incidence and management of common adverse events associated with first-line agents for relapsing multiple sclerosis (MS), including interferon beta (IFNbeta)-1a, IFNbeta-1b, glatiramer acetate, mitoxantrone, and natalizumab.
Paper Details　
Original Abstract of the Article :
First-line agents approved in the United States for treatment of relapsing multiple sclerosis (MS) include intramuscular interferon beta (IFNbeta)-1a, subcutaneous (SC) IFNbeta-1a, SC IFNbeta-1b, and SC glatiramer acetate. Intravenous mitoxantrone is the only agent approved for secondary progressive...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/03007990802329959

データ提供：米国国立医学図書館（NLM）

Managing Adverse Effects of Disease-Modifying Agents for Multiple Sclerosis

Multiple sclerosis (MS) is a complex and challenging neurological disease. This research explores the management of adverse events associated with disease-modifying agents (DMAs) used to treat relapsing MS. The study focuses on common DMAs, including interferon beta (IFNbeta)-1a, IFNbeta-1b, glatiramer acetate, mitoxantrone, and natalizumab, and their potential side effects. The study provides valuable information for healthcare providers on the management of these adverse events.

Disease-Modifying Agents: Understanding Potential Side Effects

The study highlights the potential adverse events associated with DMAs used to treat relapsing MS. The study provides a comprehensive overview of common side effects associated with these medications, including injection site reactions, flu-like symptoms, and liver function abnormalities. This information is crucial for healthcare providers to effectively manage these side effects and ensure optimal patient care.

Disease-Modifying Agents: Balancing Benefits and Risks

This research underscores the importance of balancing the benefits and risks associated with DMAs used to treat MS. The study provides valuable information for healthcare providers to effectively manage the potential side effects of these medications and ensure optimal patient care. This research highlights the ongoing efforts to develop safer and more effective treatments for MS and improve the lives of patients affected by this complex disease.

Dr.Camel's Conclusion

The study's findings emphasize the importance of careful monitoring and management of adverse events associated with DMAs used to treat MS. This research highlights the ongoing efforts to develop safer and more effective treatments for MS and improve the lives of patients affected by this complex disease.

Date :
  1. Date Completed 2009-01-22
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

18694542

DOI: Digital Object Identifier

10.1185/03007990802329959

Related Literature

Article Analysis
・Effects of natalizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.